Combination of the anti-CD30-auristatin-E antibody-drug conjugate SGN-35 with chemotherapy improves antitumor activity in Hodgkin's lymphoma

被引：0
|
作者：
Oflazoglu, E. [1 ]
Kennedy, D. [2 ]
Sievers, E. L. [2 ]
Kissler, K. M. [1 ]
Jonas, M. [3 ]
Ihle, N. C. [4 ]
Grewal, I. S. [1 ]
Gerber, H. [1 ]
机构：
[1] Seattle Genet Inc, Preclin Therapeut, Bothell, WA USA
[2] Seattle Genet Inc, Clin, Bothell, WA USA
[3] Seattle Genet Inc, Antibody Technol, Bothell, WA USA
[4] Seattle Genet Inc, Proc Chem, Bothell, WA USA
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：235 / 236
页数：2
相关论文
共 50 条
  • [21] Preclinical and Clinical Binding Properties, Internalization Kinetics, and Clinicopathological Activity of Brentuximab Vedotin (SGN-35): Novel Antibody Drug Conjugate for Anaplastic Large Cell Lymphoma and Classical Hodgkin Lymphoma.
    Fromm, Jonathan R.
    McEarchern, Julie A.
    Kennedy, Dana
    Anju, Thomas
    Shustov, Andrei R.
    Gopal, Ajay K.
    BLOOD, 2010, 116 (21) : 746 - 747
  • [22] Potent antitumor activity of the anti-CD19 auristatin antibody-drug conjugate hBU12-vcMMAE in rituximab sensitive and resistant lymphomas
    Gerber, H. P.
    Stone, I.
    Kung-Sutherland, M.
    Miyamoto, J.
    Okeley, N.
    Alley, S. C.
    Meyer, D. L.
    Sussman, D.
    Senter, P.
    Grewal, I. S.
    EJC SUPPLEMENTS, 2008, 6 (12): : 161 - 161
  • [23] Multiple Complete Responses in a Phase I Dose-Escalation Study of the Antibody-Drug Conjugate SGN-35 in Patients with Relapsed or Refractory CD30-Positive Lymphomas.
    Younes, Anas
    Forero-Torres, Andres
    Bartlett, Nancy L.
    Leonard, John P.
    Lynch, Carmel
    Kennedy, Dana A.
    Sievers, Eric
    BLOOD, 2008, 112 (11) : 370 - 370
  • [24] Complete remissions with weekly dosing of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in a phase I dose-escalation study in patients with relapsed or refractory Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL)
    Bartlett, N.
    Forero-Torres, A.
    Rosenblatt, J.
    Fanale, M.
    Horning, S. J.
    Thompson, S.
    Sievers, E. L.
    Kennedy, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [25] Anti-CD19 antibody-drug conjugate therapy in B cell non-Hodgkin lymphoma
    Saito, Chieko
    Bi, Chengfeng
    Fu, Kai
    CANCER RESEARCH, 2023, 83 (07)
  • [26] CD70 expression in multiple types of carcinomas: new targets for auristatin-based anti-CD70 antibody-drug conjugate, SGN-75
    Smith, Leia
    Kostner, Heather
    Duniho, Steven
    Nesterova, Albina
    Sutherland, May
    Yu, Changpu
    Kim, Kristine
    Gordon, Kristine
    McEarchern, Julie
    Law, Che-Leung
    Ryan, Maureen
    CANCER RESEARCH, 2009, 69
  • [27] The Antibody-Drug Conjugate Brentuximab Vedotin (SGN-35) Induced Multiple Objective Responses in Patients with Relapsed or Refractory CD30-Positive Lymphomas in a Phase 1 Weekly Dosing Study.
    Fanale, Michelle
    Bartlett, Nancy L.
    Forero-Torres, Andres
    Rosenblatt, Joseph
    Horning, Sandra J.
    Franklin, Anna R.
    Lynch, Carmel M.
    Sievers, Eric L.
    Kennedy, Dana A.
    BLOOD, 2009, 114 (22) : 1068 - 1069
  • [28] cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity
    Francisco, JA
    Cerveny, CG
    Meyer, DL
    Mixan, BJ
    Klussman, K
    Chace, DF
    Rejniak, SX
    Gordon, KA
    DeBlanc, R
    Toki, BE
    Law, CL
    Doronina, SO
    Siegall, CB
    Senter, PD
    Wahl, AF
    BLOOD, 2003, 102 (04) : 1458 - 1465
  • [29] The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models
    Hicks, Stuart W.
    Lai, Katharine C.
    Gavrilescu, L. Cristina
    Yi, Yong
    Sikka, Surina
    Shah, Prerak
    Kelly, Meghan E.
    Lee, Jenny
    Lanieri, Leanne
    Ponte, Jose F.
    Sloss, Callum M.
    Romanelli, Angela
    NEOPLASIA, 2017, 19 (09): : 661 - 671
  • [30] SGN-CD30C, an Investigational CD30-Directed Camptothecin Antibody-Drug Conjugate (ADC), Shows Strong Anti Tumor Activity and Superior Tolerability in Preclinical Studies
    Ryan, Maureen
    Lyski, Ryan
    Bou, Lauren
    Heiser, Ryan
    Grogan, Bryan
    Meyer, Dave
    Jin, Steven
    Simmons, Jessica
    Conerly, Melissa
    Senter, Peter
    Jeffrey, Scott
    BLOOD, 2020, 136
12345